Company news

Prelude Therapeutics Incorporated news in 2025

Prelude Therapeutics Incorporated's news releases, calls and decks from 2025, newest first.

View company

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

December 6, 2025

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

November 12, 2025

Prelude Therapeutics Announces Strategic Business Update

November 4, 2025

Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors

November 4, 2025

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

November 3, 2025

Prelude Therapeutics Announces Appointment of Katina Dorton, J.D., MBA to its Board of Directors

October 17, 2025

Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 14, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 2, 2025

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 6, 2025

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 1, 2025

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

March 10, 2025

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

March 5, 2025

Calls in 2025

Decks in 2025